Although the clinical significance of low-level mutant clones during IM treatment has not been completely elucidated, it is plausible that KD mutations should be identified as early as possible because they may indicate the need for therapy modification. 6 To date, direct sequencing has been the technology of choice for detecting mutant clones. However, this method has limitations in sensitivity; typically, the mutant allele contribution has to exceed 20%. 6 Denaturing high performance liquid chromatography (D-HPLC) has been suggested as a promising tool for screening of BCR-ABL KD mutations.
The outcome of intensive induction therapy in patients X70 years with acute myeloid leukemia Leukemia (2007) There continues to be controversy about the suitable upper age for intensive induction therapy in older patients with acute myeloid leukemia (AML). Some investigators have reported increasing age as a poor prognostic factor for complete remission (CR) and survival in older patients with AML, 1,2 whereas others did not observe an adverse impact of age.
3-6 A recent study from the German-Austrian AML study group showed that patients X70 years had poor survival irrespective of cytogenetics risk group. 7 These data question the utility of intensive therapy in patients X70 years.
In view of the above controversy, we evaluated the outcomes of AML patients X70 years (acute promyelocytic leukemia excluded) treated with intensive therapy at our institute as compared with those aged 60-69 years. Between 1998 and 2005, we treated 291 newly diagnosed patients X60 years (median age 68 years) with intensive therapy. This study includes 117 patients X60 years with previously reported outcomes. 6 Candidacy for induction therapy was decided on the basis of general fitness, adequate left ventricular ejection fraction (X50%) and patients' wishes to proceed with induction therapy. Of particular note, 264 patients (91%) received uniform induction therapy consisting of daunorubicin 60 mg/m 2 /day Â 3 days and cytarabine 100 mg/m 2 /day Â 7 days as described previously. 6 In a minority of patients (n ¼ 27), chemotherapy was modified owing to significant organ dysfunction according to the discretion of the treating physician. Those who did not achieve CR with one course were given a second course with mitoxantrone, etoposide and cytarabine as described previously. 6 For patients achieving CR, two courses of postremission therapy were given. Before 2002, post-remission therapy was with daunorubicin and modified course of highdose cytarabine as previously described. 6 From 2003 to 2005, first course of post-remission therapy was daunorubicin and cytarabine identical to the induction therapy and second course Letters to the Editor was with mitoxantrone (10 mg/m 2 /day Â 5 days, days 1-5) and etoposide (100 mg/m 2 /day Â 5 days, days 1-5). No differences in outcomes according to post-remission therapy strategy were seen (data not shown).
The study cohort was divided into patient groups: 60-69 years (n ¼ 171) and X70 years (n ¼ 120). Patient characteristics at diagnosis and outcome of treatment in the two groups are summarized in Table 1 . No significant differences in response to induction therapy (Table 1) or survival were noted between groups (Figure 1) . In a multivariate analysis, white blood cell count 430 Â 10 9 /l (Po0.0001), high-risk cytogenetics (Po0.0001) and Eastern Cooperative Oncology Group performance status (P ¼ 0.02) were independent predictors of survival, whereas age was not (P ¼ 0.74).
The reasons for the discrepant results between our study and the German-Austrian study are not clear. The proportion of patients X70 years in our study and the German-Austrian study do not appear very different [120/291 (41%) versus 118/361 (33%)]. However, our study showed significantly different results. We did not find any difference in CR rates according to age, whereas the German-Austrian study noted a lower CR rate in patients X70 years with non high-risk cytogenetics (39 versus 62%). 7 A possible explanation could be a higher proportion of patients with impaired performance status (PS) and co-morbidities in the group X70 years in the German-Austrian study resulting in high early mortality (EM). In a recent study from the South West Oncology Group (SWOG), age had only a modest effect on EM in patients with good PS; however, this effect was profound in patients with poor PS. 8 Of note, patients 475 years with a PS of 2 and 3 had an EM of 50 and 82%, respectively. 8 However, no data on PS or co-morbidities were provided in the German-Austrian study.
It is possible that better results in patients X70 years may be related to more careful patient selection at our center. During the study period, 477 new patients aged X60 years with a diagnosis of AML were seen at our center. Among the age groups of 60-69 (n ¼ 209), 70-80 (n ¼ 216) and 480 years (n ¼ 51), 82, 49 and 21%, respectively, were treated intensively. A decreasing proportion of patients treated intensively with increasing age may reflect selection of older patients likely to benefit from intensive therapy. It is possible that center effects may be important for the outcome of intensive therapy in older patients and these should be reported in multi-center cooperative group studies.
Based on our data, we conclude that with careful selection, the outcome of AML in patients X70 years is comparable to 
Figure 1
No difference in 3-year survival was observed in patients X70 years (14% (95% CI 8-22)) compared with patients aged 60-69 years (12% (95% CI 7-18)). 
